Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:ibrutinib
|
| gptkbp:activities |
BCL-2 inhibitor
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2016
gptkb:FDA |
| gptkbp:clinical_trial |
Phase 1
Phase 2 Phase 3 approximately 70% |
| gptkbp:contraindication |
hypersensitivity to venetoclax
|
| gptkbp:developed_by |
gptkb:Abb_Vie
|
| https://www.w3.org/2000/01/rdf-schema#label |
Venetoclax
|
| gptkbp:ingredients |
C22 H25 Cl N6 O3 S
|
| gptkbp:is_atype_of |
L01 X X40
|
| gptkbp:is_used_for |
gptkb:healthcare_organization
|
| gptkbp:side_effect |
fatigue
nausea diarrhea neutropenia |
| gptkbp:type_of |
1257044-40-8
|